Now let me finalize. Let me compare systematically:

- **SaProt (7.33)**: Structure-aware PLM, broader evaluation (10 tasks), cleaner methodology, less architecturally novel. Stronger overall paper.
- **ProteinWorkshop (6.25)**: Benchmark paper, rigorous but limited novelty as a contribution. ProteinVista has more technical novelty.
- **ProteinINR (5.75)**: Novel surface pretraining but marginal gains. ProteinVista has substantially stronger empirical results.
- **BindNet (5.67)**: Binding representation learning with data leakage concerns. ProteinVista is better executed.
- **PPIformer (5.80)**: PPI mutation prediction, divisive reviews. ProteinVista is more consistently solid.

ProteinVista sits between ProteinWorkshop (6.25) and SaProt (7.33). Its novel architecture, strong IC50 results, and excellent analysis push it above 6.25, but the framing issues (data-efficiency claim, missing controlled baseline, undocumented splits) keep it below SaProt's 7.33. I assign **6.5**.

## Summary
ProteinVista introduces a compact (123M-parameter) 3D CNN that voxelizes full-atom protein structures, is pre-trained via contrastive alignment with ESM-2 embeddings on ~500K AlphaFold-2 structures, and uses multi-view test-time augmentation for rotation robustness. The model is evaluated on three structure-dependent tasks (transporter-substrate classification, enzyme-substrate classification, and drug-target IC50 regression), where it matches or exceeds ESM-2 despite using far fewer parameters and less GPU compute. A simple ensemble with ESM-2 yields further gains, and an optimized pipeline achieves state-of-the-art on substrate prediction benchmarks.

## Strengths
- **Strong IC50 regression results**: ProteinVista achieves R² = 0.69 vs. ESM-2₆₅₀M's R² = 0.61 (p < 10⁻³⁰⁴), the clearest win on the task that most directly demands atom-level binding-pocket detail (Section 3.2, Table 2).
- **Stratified complementarity analysis**: Section 4.1 partitions the test set by sequence identity, TM-score, and pLDDT, revealing that ProteinVista dominates in high-similarity regimes while ESM-2 catches up in low-similarity regimes — and that the ensemble consistently outperforms both. This is a genuinely insightful analysis that characterizes *when* structure matters rather than just reporting aggregate metrics.
- **Well-ablated multi-view augmentation**: Reducing from 5 to 1 augmented views drops R² by 6.4% (Section 4.2), validating the importance of orientation handling. The finding that disabling augmentation during fine-tuning has negligible impact (−0.1%) is a useful practical result.
- **Concrete compute-efficiency benchmarks**: Pre-training used ~1% of ESM-2₆₅₀M's GPU-hours (48 hours on 4 A100 GPUs vs. ~7 days on 128 H100 GPUs), and training throughput is ~20× faster per 1,000 proteins (Section 4.3). These are specific, comparable metrics.
- **Honest negative result**: The paper reports that ProteinVista underperforms ESM-2 on GO-term prediction (F_max 0.57 vs. 0.62) and correctly attributes this to the task being homology-driven rather than structure-dependent (Section 3.4). This intellectual honesty strengthens credibility.
- **Practical design choices**: Adaptive grid sizing (64³–160³) per protein avoids wasting compute on empty voxels, and Gaussian density smearing reduces discretization artifacts compared to one-hot encoding (Section 2.1).

## Weaknesses

### Fatal
None.

### Major
- **Contrastive pretraining undermines the "less data" narrative**: The paper's headline claim is that ProteinVista achieves strong performance while using "more than two orders of magnitude less data" than ESM-2. However, the chosen pretraining objective (contrastive alignment against ESM-2 embeddings, Section 2.3) means ProteinVista directly distills representations from a model trained on 250M sequences. The comparison of pretraining data volumes is therefore misleading without qualification: ProteinVista's representations inherit information from ESM-2's full training corpus through the contrastive target. The Rosetta-score regression variant (which would provide a clean data-efficiency comparison) exists and is only 1.0% worse in R² (Section 4.2), but its full performance across all benchmarks is not reported. The data-efficiency claim should be qualified or the Rosetta-pretrained variant's full results should be shown.

- **Missing controlled baseline for the optimized-pipeline SOTA comparison**: Section 3.3 reports that ESM-ProteinVista_OP surpasses SPOT, ProSmith-ESP, and Fusion_ESP. But ESM-ProteinVista_OP is a complex pipeline that jointly fine-tunes MolFormer, trains a contrastive network, and ensembles ProteinVista with ESM-2₆₅₀M. The paper never reports how ESM-2₆₅₀M alone performs under this same optimized pipeline. Without that ablation, the reader cannot determine whether the SOTA gains come from ProteinVista's structural encoding or from the optimized pipeline itself. The simple ESM-ProteinVista ensemble (Table 1) does not beat SPOT on TSP (91.5% vs. 92.4%), making it plausible that the optimized pipeline applied to ESM-2 alone could reach similar numbers.

- **Train/validation/test split methodology not described**: Section 3.1 does not specify whether splits are random, temporal, or sequence-identity-based. For protein benchmarks, random splits risk inflated performance estimates because homologous proteins can appear in both train and test sets. Figure 2a confirms that test proteins with 80–100% sequence identity to training proteins exist in the evaluation, consistent with random splitting. The paper partially mitigates this concern through its transparent similarity-stratified analysis (Section 4.1), but the lack of explicit split documentation and the absence of a sequence-identity-controlled split remain significant gaps for claims about generalization.

### Minor
- **Rotation augmentation limited to a discrete symmetry group, not continuous rotations**: The augmentation uses only 90° rotations and mirror reflections (the 24-element octahedral group, Section 2.4). A protein rotated by an arbitrary angle produces a different embedding. The five-view test-time averaging mitigates this in practice, but the description of "rotation-robust representations" overstates what the augmentation achieves — it is robust to axis-aligned cube symmetries, not arbitrary SO(3) rotations.

- **Claims of outperformance on classification tasks are thin**: On ESP, ProteinVista achieves 91.8% accuracy vs. ESM-2₆₅₀M's 91.9% — essentially a tie. On TSP, the margin is 1.5 percentage points (90.8% vs. 89.3%). The abstract claims ProteinVista "outperforms sequence transformers on three benchmarks," which is technically true for TSP and IC50 but misleading for ESP. The strongest results consistently come from the ensemble, not ProteinVista alone.

- **Inconsistent Rosetta score count**: Section 2.3 states "23 in silico computed Rosetta scores" while Section 5 (Discussion) states "Regression on 33 Rosetta scores." These conflicting numbers create ambiguity about the pretraining task specification.

- **ESM-2 teacher variant unspecified**: Section 2.3 describes contrastive alignment against "ESM-2 sequence embeddings" but does not specify which ESM-2 variant serves as the teacher. This matters for reproducibility and for interpreting the data-efficiency claims.

- **Ablations limited to IC50 task**: All ablations in Section 4.2 are performed on the IC50 regression benchmark only. It is unclear whether findings (e.g., Rosetta vs. CL pretraining, resolution sensitivity, augmentation during fine-tuning) generalize to the classification tasks (TSP, ESP).

- **Fraction of cropped proteins not reported**: Section 2.1 notes that structures exceeding the 160³-voxel grid are cropped, but the paper never reports what fraction of proteins are affected.

### Trivial
- The ESM-ProteinVista_OP comparison against single-model methods (SPOT, ProSmith-ESP, Fusion_ESP) is structurally asymmetric (ensemble vs. single model), though the simple ensemble results in Table 1 partially contextualize this.

## Nice-to-Haves
- Report the Rosetta-pretrained variant's full performance across all benchmarks (TSP, ESP, IC50, GO), not just the 1.0% R² difference on IC50. If competitive, this would cleanly support the data-efficiency claim without the ESM-2 distillation caveat.
- Run ESM-2₆₅₀M through the optimized pipeline (Section 3.3) and report that result alongside ESM-ProteinVista_OP to isolate ProteinVista's contribution.
- Add a sequence-identity-based split variant (e.g., max 40% identity between train and test) to demonstrate that gains persist under stricter evaluation.
- Discuss storage mitigation strategies (on-the-fly voxelization, half-precision, compression) given the 75 GB disk cost for ~5,800 proteins.

## Removed Points
These points are flagged to be removed, treat them with caution.

- **Gaussian formula notation error** (Harsh Critic, Section 2.1): The formula on line 57 uses $\vec{v}$ both as a position and as a density value and uses linear distance in the exponent. This is clearly a parser/typesetting artifact — the intended formula is a standard Gaussian kernel. Removed per formatting-artifact rule.
- **Overinterpretation of p-values** (Harsh Critic, Section 3.2): The criticism that p < 10⁻³⁰⁴ "should not be overinterpreted as indicating large effect sizes" does not identify an actual problem — the paper reports p-values alongside effect-size metrics (R², accuracy differences) and does not claim they indicate effect size. Removed as not a real issue.
- **Disk I/O speculation in compute comparison** (Harsh Critic, Section 4.3): The concern that the 20s training throughput "may not include time to load and voxelize structures from disk" is speculative. The paper reports training throughput; whether I/O is a bottleneck is unknown from the paper alone. Removed as speculative.
- **"Missing Parts" benchmarks beyond binding prediction** (Harsh Critic): The suggestion to evaluate on mutation effect prediction or protein-protein interaction tasks is scope creep — the paper is explicitly about structure-dependent binding prediction. Moved to Nice-to-Haves.

## Novel Insights
The stratified similarity analysis (Section 4.1, Figure 2a–c) provides a genuinely novel lens on when structure-based encoders help versus when sequence-based ones suffice. The finding that ProteinVista dominates at high sequence/structure similarity to training data while ESM-2 catches up in novel-fold regimes is not just a performance comparison — it characterizes the *type* of information each modality captures and their complementarity. The ensemble's consistent superiority across all bins suggests that sequence and structure signals are additive rather than redundant, which is a more nuanced conclusion than "structure beats sequence." This analysis approach (binning by similarity and reporting per-bin model rankings) could serve as a template for evaluating future structure encoders.

## Suggestions
- Qualify the "less data" claim in the abstract and introduction to acknowledge that the contrastive pretraining objective transfers information from ESM-2's larger training corpus. A formulation like "ProteinVista is pretrained on only ~500K structures (vs. 250M sequences for PLMs), using contrastive distillation from ESM-2" would be accurate and still impressive.
- Add the ESM-2₆₅₀M-only result through the optimized pipeline (Section 3.3) — this is the single most important missing experiment for the SOTA claim.
- Explicitly describe the split methodology in Section 3.1 and, ideally, report results under a sequence-identity-controlled split.
- Resolve the 23 vs. 33 Rosetta scores inconsistency between Section 2.3 and Section 5.
- Specify which ESM-2 variant serves as the contrastive teacher in Section 2.3.

### Anchor comparison summary
- **Round 1 anchors**: LEGO (3.00), ProteinAdapter (3.40), ProteiNexus (3.67), RNA Contrastive (4.33), ProteinINR (5.75), ProteinWorkshop (6.25), FoldFlow/ProtComposer/Walk-Jump/GeoBFN (8.00). Initial bracket: 6–8.
- **Round 2 anchors**: BindNet (5.67), ProteinINR (5.75), PPIformer (5.80), ProteinWorkshop (6.25), SaProt (7.33). Narrowed to 6.0–7.5.
- ProteinVista is stronger than BindNet (5.67), ProteinINR (5.75), and ProteinWorkshop (6.25) due to its novel architecture, stronger empirical IC50 results, and insightful stratified analysis. It is weaker than SaProt (7.33) due to narrower evaluation, framing issues around the data-efficiency claim, missing controlled baselines, and undocumented split methodology. Final score: **6.5**.

MY FINAL SCORE: <score>6.5</score>
MY FINAL DECISION: <decision>Accept</decision>